The matrix protein pp65341-350: A peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele

Transfusion

Volumn 43, Issue 11, 2003, Pages 1567-1574

  Provenzano, Maurizio ^a   Lim, Jong Baeck ^b   Mocellin, Simone ^b   Monsurro, Vladia ^b   Bettinotti, Maria ^b   Marincola, Francesco M ^b   Stroncek, David F ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA A24 ANTIGEN; MESSENGER RNA; PEPTIDE DERIVATIVE; PHENYLALANINE; PROTEIN PP65; SCLEROPROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLELISM; AMINO ACID COMPOSITION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MALE; MEMORY CELL; MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ALLELES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL DIVISION; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; MONOCYTES; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; RNA, MESSENGER; VIRAL MATRIX PROTEINS;

EID: 0242608343     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00564.x     Document Type: Article

References (32)

1. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97:1232-40.
2. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
3. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001;98:505-12.
4. Wills MR, Carmichael A, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
5. Grefte J, van der Gun B, Schmolke S, et al. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 1992;73:2923-32.
6. Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90:1751-67.
7. Khattab BA, Lindenmaier W, Frank R, Link H. Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes. J Med Virol 1997;52: 68-76.
8. Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998;4:975-8.
9. Solache A, Morgan CL, Dodi AI, et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 1999;163:5512-8.
10. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8 (+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001;98:1872-81.
11. Akiyama Y, Maruyama K, Mochizuki T, et al. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol Lett 2002;83:21-30.
12. Provenzano M, Mocellin S, Bettinotti M, et al. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother 2002;25:342-51.
13. Bednarek MA, Sauma SY, Gammon MC, et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol 1991;147:4047-53.
14. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000;92:1336-44.
15. Provenzano M, Rossi CR, Mocellin S. The usefulness of quantitative real-time PCR in immunogenetics. ASHI Q 2001;25:89-91.
16. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immun Meth 1996;196:137-51.
17. Velders MP, Macedo MF, Provenzano M, et al. Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen. J Cell Biochem 2001;82:155-62.
18. Mocellin S, Fetsch P, Abati A, et al. Laser scanning cytometry evaluation of MART-1, gp100 and HLA-A2 expression in melanoma metastases. J Immunother 2001;24:447-58.
19. Kawashima I, Tsai V, Southwood S, et al. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999;59:431-5.
20. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001;97:994-1000.
21. Falk K, Rotzschke O, Stevanovic S, et al. Analysis of a naturally occurring HLA class I-restricted viral epitope. Immunology 1994;82:337-42.
22. BenMohamed L, Krishnan R, Longmate J, et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T (H) response. Hum Immunol 2000;61:764-79.
23. Bilsborough J, Panichelli C, Duffour MT, et al. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens 2002;60:16-24.
24. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
25. Rammensee HG, Bachmann J, Stevanovic S. MHC ligands and peptide motifs. In: Landes bioscience. Austin, TX: Blackwell Science, 1997:1-459.
26. Rotzschke O, Falk K, Stevanovic S, et al. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 1992;22:2453-6.
27. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-80.
28. Grigoleit U, Riegler S, Hebart H, et al. 43rd ASH Annual Meeting (abstract). Blood 2000;98:950a.
29. Jahn G, Stenglein S, Riegler S, et al. Human cytomegalovirus infection of immature dendritic cells and macrophages. Intervirology 1999;42:365-72.
30. Froberg MK, Adams A, Seacotte N, et al. Cytomegalovirus infection accelerates inflammation in vascular tissue overexpressing monocyte chemoattractant protein-1. Circ Res 2001;89:1224-30.
31. Kitajima H, Okubo Y, Honda J et al. Interleukin-4 is needed for the infection of monocytes by human cytomegalovirus. Intervirology 2001;44:264-70.
32. Wagenknecht DR, Getty RR, Britton RM, et al. Caucasian US normal. In: HLA 1998. Gjertson DW, Terasaki PI, eds. Lenexa, KS: American Society of Histocompatibility and Immunogenetics, 1998:249.